AstraZeneca has paid $85m upfront to develop Tregs against two autoimmune conditions, type 1 diabetes and inflammatory bowel disease
AstraZeneca is to work with Quell Therapeutics to develop its Treg cell therapies in two autoimmune disease areas, paying out $85m upfront in a deal which could be worth well over $2bn.
The UK pharma company is currently enjoying huge success, most notably its small molecule cancer drug Tagrisso (osimertinib) and antibody drug conjugate cancer therapy Enhertu (trastuzumab deruxtecan), but the Quell deal shows the company
Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.
The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).
The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.
